Upon diagnosed with lymph node recurrence, the patient was treated with two courses of capecitabine + oxaliplatin without trastuzumab because of a human epidermal growth factor receptor 2 (HER2)-negative gastric cancer. Here, ERBB2 is linked to gastric cancer.